AC Immune Company
AC Immune is a Swiss biopharmaceutical company that focuses on developing therapeutic and diagnostic products for neurodegenerative diseases caused by misfolding proteins. They have three product candidates in clinical trials and two proprietary technology platforms that create antibodies, small molecules, and vaccines for a broad range of neurodegenerative indications. AC Immune is a global leader in precision medicine for neurodegenerative diseases, including Alzheimer's and Parkinson's.
Connections
Funding Status:
IPO
Industry:
BioTech
Estimated Revenue:
$10M to $50M
Technology:
Therapeutic and Diagnostics
Headquarters:
Lausanne, Vaud
Total Funding:
117439497
Last Funding Date:
09 05 16
Last Funding Type:
Series E
Employee Number:
51-100
Investors Number:
2
Founded Date:
2003